Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Subcutaneous Efalizumab for Steroid Refractory GVHD
NCT00489216Phase 2Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Dec 2006
- Primary completion
- Jun 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of efalizumab in graft-versus-host disease (GVHD), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Dec 2006; status: terminated.
02
Drugs
efalizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00489216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00489216.